艾米替诺福韦治疗慢性乙型肝炎患者的疗效分析
Analysis of theEfficacy of Emetinofovir in Treating Patients with Chronic Hepatitis B
于桂芹 1余嘉慧1
作者信息
- 1. 扬州市江都区第三人民医院感染科,江苏扬州 225200
- 折叠
摘要
目的 探究艾米替诺福韦治疗慢性乙型肝炎患者的临床效果.方法 选择2021年6月至2024年3月医院收治的慢性乙型肝炎患者96例,以随机数表法分成对照组(48例,采用恩替卡韦治疗)与观察组(48例,采用艾米替诺福韦治疗).对两组临床疗效、肝功能、肝纤维化指标与不良反应进行比较.结果 观察组治疗总有效率高于对照组,P＜0.05.治疗后观察组各肝功能指标、肝纤维化指标水平均较对照组低,P＜0.05.观察组不良反应率较对照组低,P＜0.05.结论 艾米替诺福韦治疗慢性乙型肝炎的疗效可靠,能改善患者肝功能并抑制肝纤维化进程,且不良反应少.
Abstract
Objective:To Objective to explore the clinical effect of Amitenofovir in the treatment of patients with chronic hepatitis B.Methods:96 patients with chronic hepatitis B admitted to our hospital from June 2021 to March 2024 were randomly divided into control group(48 cases treated with entecavir)and observation group(48 cases treated with emtenofovir).The clinical efficacy、liver function、liver fibrosis index and adverse reactions were com-pared between the two groups.Results:Higher efficiency in the observation group compared to the control group,P＜0.05.After treatment,the levels of liver function indexes and liver fibrosis indexes in the observation group were lower than those in the control group,P＜0.05.Fewer adverse reactions in the observation group than in the con-trol group,P＜0.05.Conclusion:Amitenofovir is effective in the treatment of patients with chronic hepatitis B,which can significantly improve the liver function and inhibit liver fibrosis,and the drug safety is high.
关键词
艾米替诺福韦/慢性乙型肝炎/肝功能/肝纤维化/不良反应Key words
Emtinofovir/Chronic hepatitis B/Liver function/Hepatic fibrosis/Adverse effects引用本文复制引用
出版年
2024
国家科技期刊平台
NSTL
万方数据